Menu
BASEL, Switzerland - October 31, 2022 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, will be hosting an enlightening panel discussion, “Hope or Hype?: The importance of Multimodal Data Integration to Advance Precision Medicine” at the BioData World Congress. The panel discussion and congress will take place with physical attendance, in Basel, Switzerland on November 9, 2022 at 12:05 p.m. CET at the Congress Center Basel.
Peter Casasanto, Chief BioPharma Officer at SOPHiA GENETICS, will moderate industry experts including:
These esteemed panelists will discuss topics such as the importance of multimodal data integration to advance precision medicine, the role of A.I. and real-world data in clinical practice, how we can scale the use of A.I. in clinical practice, and what the main challenges are to apply A.I. in healthcare.
The BioData World Congress is Europe’s largest congress covering big data in pharmaceutical development and healthcare. Interested parties can register for the conference here.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
###
Media Contact:
Kelly Katapodis
Senior Manager, Media & Communications
[email protected]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
